While Neuralink often brands itself as a pioneer in brain-computer interfaces (BCIs), China’s BCI sector is rapidly transitioning from experimental research to large-scale commercialization. A growing ecosystem of startups — developing both implantable and noninvasive technologies — is gaining momentum through expanding clinical trials, coordinated national policy support, and increasing investor interest.

Among the entrepreneurs driving this movement is Phoenix Peng, co-founder of NeuroXess, which develops implantable BCI systems, and founder and CEO of Gestala, focused on noninvasive ultrasound-based interfaces. Peng argues that China’s progress is rooted not just in ambition but in structural support. Provinces including Sichuan, Hubei, and Zhejiang have already established medical service pricing frameworks for BCI treatments, accelerating their pathway into the national medical insurance system — a key milestone for large-scale healthcare adoption.

Over the next three to five years, Peng expects BCIs to remain concentrated in clinical applications, particularly for treating neurological disorders, paralysis, and other medical conditions. With insurance coverage expanding, he projects the domestic BCI market could reach multibillion-dollar scale. However, he believes the long-term potential extends far beyond healthcare.

“I have always maintained that neuroscience and AI are two sides of the same coin,” Peng said, predicting eventual deep integration between biological and artificial intelligence. In his view, BCIs will act as a high-bandwidth bridge between carbon-based human cognition and silicon-based AI systems — enabling direct brain-to-AI interaction and unlocking vast commercial possibilities.

China’s national strategy reflects that ambition. In August 2025, the country’s industry ministry, alongside six other government agencies, released a roadmap aimed at accelerating BCI development. The plan outlines key technological milestones by 2027, standardized industry frameworks, and a complete domestic supply chain by 2030. The ultimate goal: foster globally competitive BCI companies while supporting smaller specialized firms to strengthen the broader innovation ecosystem.

With policy alignment, investor backing, and expanding clinical validation converging, China’s BCI industry appears poised to move from early-stage experimentation toward structured industrial growth — positioning itself as a major contender in the global race to merge neuroscience with artificial intelligence.